The treatment of negative symptoms: Pharmacological and methodological issues

British Journal of Psychiatry

Volumn 168, Issue MAY SUPPL. 29, 1996, Pages 17-22

  Carpenter Jr , William T ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PROPRANOLOL; RITANSERIN; PSYCHOTROPIC AGENT;

HUMAN; NEGATIVE SYNDROME; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; DEPRESSION; DRUG COMBINATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DEPRESSION; DRUG THERAPY, COMBINATION; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0029896488     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000298279     Document Type: Review

References (44)

1. ALPERT, M. & FRIEDHOFF, A. J. (1980) An un-dopamine hypothesis of schizophrenia. Schizophrenia Bulletin, 6, 387-389.
2. ANDREASEN, N.C. (1983) The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa Press.
3. ANGST, J., STASSEN, H. H. & WOGGON, B. (1989) Effect of neuroleptics on positive and negative symptoms and the deficit state. Psychopharmacology, 99, S41-S46.
4. BORISON, R. L., PATHIRAJA, A. P., DIAMOND, B. I., et al (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin, 28, 213-218.
5. BREIER, A., BUCHANAN, R. W., KIRKPATRICK, B., et al (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151, 20-26.
6. BUCHANAN, R. W., KIRKPATRICK, B., HEINRICH, D. W., et al (1990) Clinical correlates of the deficit syndrome of schizophrenia. American Journal of Psychiatry, 147, 290-294.
7. _, BREIER, A., KIRKPATRICK, B., et al (1993) Structural abnormalities in deficit vs. non-deficit schizophrenia. American Journal of Psychiatry, 150, 59-65.
8. _ & CARPENTER, W. T. (1994) Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. Journal of Nervous and Mental Disease, 182, 193-204.
9. _, BRANDES, M. & BREIER, A. (1996) Pharmacological strategies for treating negative symptoms. In The New Pharmacotherapy of Schizophrenia (ed. A. Breier). Washington, DC: American Psychiatric Press (in press).
10. CARPENTER, W. T., JR, HEINRICH, D. W. & ALPHS, L. D. (1985) Treatment of negative symptoms. Schizophrenia Bulletin, 11, 440-452.
11. _, _ & WAGMAN, A. M. I. (1988) Deficit and non-deficit forms of schizophrenia: the concept. American Journal of Psychiatry, 145, 578-583.
12. _, BUCHANAN, R. W., KIRKPATRICK, B., et al (1993) Strong inference, theory testing, and the neuroanatomy of schizophrenia. Archives of General Psychiatry, 50, 825-831.
13. CESKOVA, E. & SVESTKA, J. (1993) Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry, 26, 121-124.
14. CHOUINARD, G., JONES, B., REMINGTON, G., et al (1993) A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 25-40.
15. CHRISTISON, G. W., KIRCH, D. G. & WYATT, R. J. (1991) When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin, 17, 217-245.
16. CLAUS, A., BOLLEN, J., DECUYPER, H., et al (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica, 85, 285-305.
17. DAVIS, K. L., KAHM, R. S., KO, G., et al (1991) Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry, 148, 1474-1481.
18. FENTON, W. S. & MCGLASHAN, T. H. (1991) Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Archives of General Psychiatry, 48, 978-986.
19. GOLDBERG, S. C. (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophrenia Bulletin, 11, 453-456.
20. HEINRICH. K., KLIESER, E., LEHMANN, E., et al (1994) Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Progress in Neuropsychopharmacology and Biological Psychiatry, 18, 129-137.
21. KANE, J. M. & MARDER, S. R. (1993) Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin, 19, 287-302.
22. _, HONIGFELD, G., SINGER, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
23. KAY, S. R., OPLER, L. A. & LINDENMAYER, J. P. (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Research, 23, 99-110.
24. KEITH, S. J., FOR THE TSS COLLABORATIVE STUDY GROUP (1992) Influence of dose reduction and family treatment on cross-sectional measures. Report from the NIMH Schizophrenia Treatment Strategies Study, p. 63.
25. KIRKPATRICK, B., BUCHANAN, R. W., MCKENNEY, P. D., et al (1989) The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Research, 30, 119-123.
26. KRAEPELIN, E. (1919) Dementia Praecox and Paraphrenia (trans. R. M. Barclay, 1971). Huntington: Robert F. Kreiger.
27. KRAWIECKA, M., GOLDBERG, D. & VAUGHAN, M. (1977) A standardised psychiatric assessment for rating chronic psychiatric patients. Acta Psychiatrica Scandinavica, 55, 299-308.
28. LIDDLE, P. F. (1987) The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. British Journal of Psychiatry, 151, 145-151.
29. MARDER, S. R. & MEIBACH, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
30. MAYERHOFF, D. I., LOEBEL, A. D., GEISLER, S. H., et al (1992) The deficit state in a prospective study of first episode schizophrenia (abstract). Journal of Schizophrenia, 6, 168-169.
31. MELTZER, H. Y. (1991) Pharmacologic treatment of negative symptoms. In Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications (eds J. F. Greden & R. Tandon), pp. 217-231. Washington, DC: American Psychiatric Press.
32. _ (1992a) Treatment of the neuroleptic non-responsive schizophrenic patient. Schizophrenia Bulletin, 18, 515-542.
33. _ (1992b) Clozapine: pattern of efficacy in treatment-resistant schizophrenia. In Novel Antipsychotic Drugs (ed. H. Y. Meltzer). New York: Raven Press.
34. _, SOMMERS, A. A. & LUCHINGS, D. J. (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. Journal of Clinical Psychopharmacology, 6, 329-338.
35. _, BATANI, B., KWON, K. Y., et al (1989) A prospective study of clozapine in treatment-resistant schizophrenia patients. I. Preliminary report. Psychopharmacology, 99 (suppl.), S68-S72.
36. MILLER, D. D., PERRY, P. J., CADORET, R. J., et al (1994) Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Comprehensive Psychiatry, 35, 8-15.
37. OPLER, L. A., ALBERT, D. & RAMIREZ, P. M. (1994) Psychopharmacologic treatment of negative schizophrenic symptoms. Comprehensive Psychiatry, 35, 16-28.
38. OVERALL, J. E. & GORHAM, D. R. (1962) Brief Psychiatric Rating Scale. Psychological Reports, 10, 799-812.
39. SCHOTTE, A., JANSSEN, P. G., MEGENS, A. A., et al (1993) Occupancy of neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Research, 631, 191-202.
40. STRAUSS, J. S. & CARPENTER, W. T. (1972) 4-Hydroxydopamine, noradrenergic reward, and schizophrenia. Science, 175, 921-922.
41. TAMMINGA, C. A., THAKER, G. K., BUCHANAN, R., et al (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Archives of General Psychiatry, 49, 522-530.
42. TAYLOR, M. A. & ABRAMS, R. (1978) A rating scale for emotional blunting. American Journal of Psychiatry, 135, 226-229.
43. WILMS, G., VAN ONGEVAL, C., BAERT, A. L., et al (1992) Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients. Acta Psychiatrica Scandinavica, 85, 306-312.
44. WING J. & BROWN, G. (1970) Institutionalism and Schizophrenia. Cambridge: Cambridge University Press.